Patients with osteoporosis are at increased risk of suffering fractures due to a loss in bone strength. These fractures place a considerable burden on public health systems, and significant unmet need remains for osteoporosis therapies that are safer and more efficacious, particularly in reducing the risk of nonvertebral fractures (e.g., hip fractures). Research carried out by DRG for their latest report on the G7 (United States, Japan, Germany, France, Italy, Spain, United Kingdom) osteoporosis drug therapy market (2016-2026) forecasts an increase in annual sales from $5.6 billion in 2016 to $9.1 billion in 2026.

The primary drivers of growth in the osteoporosis drug therapy market will be the launches of Radius Health’s Tymlos (abaloparatide), Amgen/UCB’s Evenity (romosozumab), and an abaloparatide transdermal patch. There is significant enthusiasm amongst interviewed key opinion leaders for these therapies due to their strong efficacy data and favorable mechanisms of action. These drugs represent the first major launches into the osteoporosis market since Amgen’s Prolia (denosumab) in 2010. Further increases in market value will be created by an increasingly prevalent population.

“I think all three of these agents have great data and they're three pretty damn good drugs. I think we'll use whichever one we can get.” Physician, United States.

DRG’s research finds that low diagnosis and drug-treatment rates will continue to restrict the potential of the overall osteoporosis market. These low rates are caused by several factors, including the largely asymptomatic nature of osteoporosis; poor education about and awareness of the disease; low rates identifying and treating patients at high risk of fracture; poor access to DXA scanners in some regions; and patient fear of the rare adverse side effects associated with some treatments. Additionally, the entrenched use of less-expensive generic bisphosphonates will continue to dominate the market, especially in first-line treatment.

The Osteoporosis Disease Landscape & Forecast report also provides analysis of emerging therapies, including coverage of the early-stage pipeline, which we find to be relatively sparse. This likely reflects the safety issues that often arise in clinical trials of osteoporosis therapies and the difficulty breaking into the osteoporosis market, in which first-line treatment with generic agents dominates. Indeed, development of several late-stage osteoporosis therapies, which were expected to contribute to strong market growth, has been discontinued in the last five years.

The Osteoporosis Disease Landscape & Forecast report was produced by David Rees, M.Biochem., Ph.D, a Business Insights Analyst with the Cardiovascular, Metabolic, and Renal Disorders team at Decision Resources Group. Prior to joining Decision Resources Group, Dr. Rees was a Postdoctoral Research Associate at Imperial College London, and the Institute of Cancer Research. For his doctoral research, he studied the structures of molecular machines in the Nobel Prize winning laboratory of Prof. Sir John Walker at the University of Cambridge. Dr. Rees earned his undergraduate M.Biochem. from the University of Bath.

Molina's hunt to grab small MCOs expands growth into new markets

View Now